References
- Schüller, H., Klein, F., Lübbert, M. et al. Hemolytic crisis in
a patient treated with eculizumab for paroxysmal nocturnal
hemoglobinuria possibly triggered by SARS-CoV-2 (COVID-19): a case
report. Ann Hematol (2020).
https://doi.org/10.1007/s00277-020-04318-6
- Risitano, A., Maciejewski, J., Muranski, P. et al. Large
granular lymphocyte (LGL)-like clonal expansions in paroxysmal
nocturnal hemoglobinuria (PNH) patients. Leukemia 19,217–222 (2005). https://doi.org/10.1038/sj.leu.2403617
- Jia Yu, Xuan Yuan, Hang Chen, Shruti Chaturvedi, Evan M. Braunstein,
Robert A. Brodsky; Direct activation of the alternative complement
pathway by SARS-CoV-2 spike proteins is blocked by factor D
inhibition. Blood 2020; 136 (18): 2080–2089. doi:
https://doi.org/10.1182/blood.2020008248
- Hrishikesh S. Kulkarni, John P. Atkinson; Targeting complement
activation in COVID-19. Blood 2020; 136 (18): 2000–2001. doi:
https://doi.org/10.1182/blood.2020008925
- Risitano AM. Paroxysmal nocturnal hemoglobinuria and the complement
system: recent insights and novel anticomplement strategies. Adv Exp
Med Biol. 2013;735:155-72. doi: 10.1007/978-1-4614-4118-2_10. PMID:
23402025.